Agonistic Autoantibodies to the α 1-Adrenergic Receptor and the β 2-Adrenergic Receptor in Alzheimer's and Vascular Dementia

Scandinavian Journal of Immunology

Volumn 75, Issue 5, 2012, Pages 524-530

  Karczewski, P ^a   Hempel, P ^a   Kunze, R ^b   Bimmler, M ^c  

^a ERDE AAK Diagnostik GmbH   (Germany)

^b ERDE eV   (Germany)

^c MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR; IMMUNOGLOBULIN G;

ADULT; AGED; ALZHEIMER DISEASE; ANTIBODY AFFINITY; ANTIBODY COMBINING SITE; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; CALCIUM CELL LEVEL; CALCIUM MOBILIZATION; CHO CELL; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEART MUSCLE CELL; HUMAN; HUMAN CELL; IMMUNOADSORPTION; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MULTIINFARCT DEMENTIA; PRIORITY JOURNAL;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ANIMALS; AUTOANTIBODIES; CALCIUM; CELLS, CULTURED; DEMENTIA, VASCULAR; FEMALE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PLAQUE, ATHEROSCLEROTIC; RATS; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, ADRENERGIC, BETA-2;

EID: 84859390854     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/j.1365-3083.2012.02684.x     Document Type: Article

References (29)

1. Ni Y, Zhao X, Bao G et al. Activation of beta2-adrenergic receptor stimulates gamma-secretase activity and accelerates amyloid plaque formation. Nat Med 2006;12:1390-6.
2. Xu W, Qiu C, Gatz M, Pedersen NL, Johansson B, Fratiglioni L. Mid- and late-life diabetes in relation to the risk of dementia: a population-based twin study. Diabetes 2009;58:71-7.
3. Breteler MM. Vascular risk factors for Alzheimer's disease: an epidemiologic perspective. Neurobiol Aging 2000;21:153-60.
4. De la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence. Stroke 2002;33:1152-62.
5. Desmond DW, Moroney JT, Sano M, Stern Y. Incidence of dementia after ischemic stroke. Results of a longitudinal study. Stroke 2002;33:2254-62.
6. 1-adrenergig receptor antibodies in patients with primary hypertension. Hypertension 1997;29:678-82.
7. Liao Y-H, Wei Y-M, Wang M, Wang Z-H, Yuan H-T, Cheng L-X. Autoantibodies against the AT1-receptor and α1-adrenergic receptor in patients with hypertension. Hypertens Res 2002;25:641-6.
8. 1 receptor. J Clin Invest 1999;103:945-95.
9. Jahns R, Boivin V, Hein L et al. Direct evidence for a β1-adrenergic receptor-directed autoimmune attack as a cause of idiotypic dilated cardiomyopathy. J Clin Invest 2004;113:1419-29.
10. Zhou CC, Zhang Y, Irani R et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008;14:855-62.
11. 1-adrenergic receptor autoantibodies in refractory hypertension. PLoS ONE 2008;3:e3742.
12. Zhou Z, Liao Y-H, Wei Y et al. Cardiac remodelling after long-term stimulation by antibodies against the α1-adrenergic receptor in rats. Clin Immunol 2005;114:164-73.
13. Zhou Z, Liao Y, Li L et al. Vascular damages in rats immunized by alpha1-adrenoceptor peptides. Cell Mol Immunol 2008;5:349-56.
14. Hempel P, Karczewski P, Kohnert K-D et al. Sera from patients with type 2 diabetes contain agonistic autoantibodies against G protein-coupled receptors. Scand J Immunol 2009;70:159-60.
15. Halle W, Wollenberger A. Differentiation and behaviour of isolated embryonic and neonatal heart cells in a chemically defined medium. Am J Cardiol 1970;25:292-9.
16. Wallukat G, Wollenberger A, Morwinski R, Pitschner HF. Anti-beta 1-adrenoceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406.
17. Magnusson Y, Wallukat G, Waagstein F, Hjalmarson A, Hoebeke J. Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the β1-adrenoceptor with positive chronotropic effect. Circulation 1998;89:2760-7.
18. 1-adrenergen Rezeptor bei Myokarditis und dilatativer Kardiomyopathie.: Lokalisation von zwei Epitopen. Z Kardiol 1992;81 (Suppl. 4):79-83.
19. 1-adrenergic receptors in patients with malignant hypertension. Lancet 1994;344:1660-3.
20. Karczewski P, Haase H, Hempel P, Bimmler M. Agonistic antibody to the α1-adrenergic receptor mobilizes intracellular calcium and induces phosphorylation of a cardiac 15-kDa protein. Mol Cell Biochem 2010;333:233-42.
21. Daeron M. FC receptor biology. Annu Rev Immunol 1997;15:203-34.
22. Demuro A, Parker I, Stutzmann GE. Calcium signaling and amyloid toxicity in Alzheimer disease. J Biol Chem 2010;285:12463-8.
23. Arshavsky YI. Alzheimer's disease, brain immune privilege and memory: a hypothesis. J Neural Transm 2006;113:1697-707.
24. Levin EC, Acharya NK, Han M et al. Brain-reactive autoantibodies are nearly ubiquitous in human sera and may be linked to pathology in the context of blood-brain barrier breakdown. Brain Res 2010;1345:212-32.
25. D'Andrea MR. Evidence linking neuronal cell death to autoimmunity in Alzheimer's disease. Brain Res 2003;982:19-30.
26. Bowman GL, Kaye JA, Moore M, Waichunas D, Carlson NE, Quinn JF. Blood-brain barrier impairment in Alzheimer disease. Stability and functional significance. Neurology 2007;68:1809-14.
27. Mawuenyega KG, Sigurdson W, Ovod V et al. Decreased clearance of CNS β-amyloid in Alzheimer's disease. Science 2010;330:1774.
28. Müller J, Wallukat G, Dandel M et al. Immunoglobulin adsorption in patients with idiopathic dilated cardiomyopathy. Circulation 2000;101:385-91.
29. Staudt A, Schaper F, Stangl V et al. Immunohistological changes in dilated cardiomyopathy induced by immunoadsorption therapy and subsequent immunoglobulin substitution. Circulation 2001;103:2681-6.